This antibody is stable for greater than six months when held at -20° C in a manual defrost freezer or at -70°C. Upon thawing, the antibody can be stored at 2° - 8° C for at least 1 month without detectable loss of activity. Avoid repeated freeze-thaw cycles.
A liquid formulation in physiologic saline with 0.1% NaN3.
0.1% Sodium Azide
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for G9a/EHMT2 Antibody (A8620A) [Unconjugated]
histone-lysine N-methyltransferase, H3 lysine-9 specific 3
HLA-B associated transcript 8
Lysine N-methyltransferase 1C
Histone H3 Lys 9 (H3-K9) methylation is a crucial epigenetic marker for transcriptional silencing. G9a is the major mammalian H3-K9 methyltransferase that targets euchromatic regions and is essential for mouse embryogenesis.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our G9a/EHMT2 Antibody (A8620A) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.